Serimmune Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 23
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $12M
Latest Deal Amount
  • Investors
  • 4

Serimmune General Information

Description

Developer of an immune mapping platform intended to map circulating antibodies to their diverse antigens. The company's ml-based platform applies bacterial display peptide libraries, next-generation sequencing, and custom bioinformatics to map the distinct antibodies within a repertoire to antigens associated with infections, allergens, microbiome organisms, autoimmune diseases and cancers, enabling medical practitioners to combat infectious and autoimmune diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Decision/Risk Analysis
Primary Office
  • 150 Castilian Drive
  • Suite 100
  • Goleta, CA 93117
  • United States
+1 (805) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Serimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 11-Sep-2020 $12M 000.00 0000 Completed Generating Revenue
4. Early Stage VC 20-Jun-2017 000 000.00 Completed Generating Revenue
3. Early Stage VC (Series B) 30-Dec-2016 00.00 00.000 0000 Completed Generating Revenue
2. Grant 01-Jan-2016 $225K $850K Completed Generating Revenue
1. Early Stage VC (Series A) 13-Jan-2015 $850K $850K 00.000 Completed Generating Revenue
To view Serimmune’s complete valuation and funding history, request access »

Serimmune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 988,369 $0.000100 $0.86 $0.86 1x $0.86 8.86%
To view Serimmune’s complete cap table history, request access »

Serimmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an immune mapping platform intended to map circulating antibodies to their diverse antigens. The company's
Other Healthcare Technology Systems
Goleta, CA
23 As of 2021
000.00
000 0000-00-00
00000000000 000.00

00000000

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
0000000000000
Seattle, WA
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

0000000

eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
00000 0000000000 0000000000 0000000
New York, NY
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Serimmune Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptive Biotechnologies Formerly VC-backed Seattle, WA 000 00000 00000000 00000
0000000 Venture Capital-Backed New York, NY 00 000.00 00000000000 000.00
00000000 000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000000 0000000000 Venture Capital-Backed Pittsburgh, PA 00 000.00 0000000000 0 000.00
000000 Formerly VC-backed Ghent, Belgium 000 00000 000000&0 00000
You’re viewing 5 of 13 competitors. Get the full list »

Serimmune Executive Team (3)

Name Title Board Seat Contact Info
Noah Nasser Chief Executive Officer & Board Member
Patrick Daugherty Ph.D Co-Founder, Board Member & President
John Shon MD Chief Technology Officer
To view Serimmune’s complete executive team members history, request access »

Serimmune Board Members (5)

Name Representing Role Since
Bill Welch Serimmune Board Member 000 0000
Kristin Loomis Serimmune Board Member 000 0000
Nicholas Naclerio Ph.D Illumina Ventures Board Member 000 0000
Noah Nasser Serimmune Chief Executive Officer & Board Member 000 0000
Thomas Willis Ph.D Illumina Ventures Board Member 000 0000
To view Serimmune’s complete board members history, request access »

Serimmune Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Serimmune Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Illumina Ventures Venture Capital Minority 000 0000 000000 0
LabCorp Ventures Corporate Venture Capital Minority 000 0000 000000 0
Merck Corporation Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Serimmune’s complete investors history, request access »